Portal de investigación
- Inicio
- Proyectos y Estudios
- A Randomised, Open-label, Controlled, Multicentre, Phase 2 Trial of First-line Treatment With Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Paediatric Participants With Steroid-refractory Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation (BALDER Trial).
A Randomised, Open-label, Controlled, Multicentre, Phase 2 Trial of First-line Treatment With Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Paediatric Participants With Steroid-refractory Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation (BALDER Trial).
Datos básicos
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
MEDAC GESELLSCHAFT FUER KLINISCHE SPEZIALPRAPAERATE MBH
Cita
A Randomised, Open-label, Controlled, Multicentre, Phase 2 Trial of First-line Treatment With Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Paediatric Participants With Steroid-refractory Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation (BALDER Trial). (MC-MSC.2/aGvHD). MEDAC GESELLSCHAFT FUER KLINISCHE SPEZIALPRAPAERATE MBH. 2024IP:JOSÉ MARÍA FERNÁNDEZ NAVARRO.